Urch Publishing | Publication

Therapeutic

Title

Emerging Cancer Therapies

Sub title

Markets and Business Opportunities

Author

Dr Brian Minter

Publication date

June 2002

ISBN

Pages

Information currently unavailable

Price

pdf n/a | print £875

Summary

On a global scale, there are approximately 11 million new cases of cancer every year of which 1.8 million cases occur in the US. The high incidence of the disease, its life-threatening nature and its difficult management has resulted in a surge of interest from the pharmaceutical industry during the last decade. At the current time, sales of products used to treat cancer are close to $17 billion. More than 400 companies are investigating new products and approaches for the treatment of cancer and there are close to 450 products in clinical trials of which 80 are in phase III. Just under half of the products in clinical trials are based on biological agents such as vaccines, monoclonal antibodies, cytokines, genes coding for cytokines and protein conjugates. Breast cancer and non-small cell lung cancer have received the most attention, with respectively 100 and 90 products in clinical trials. There are more than 1000 products undergoing preclinical in-vivo trials. There is a wide range of activity surrounding the licensing of products in development with deals ranging from several hundreds of thousands of dollars for technology transfer, up to many hundreds of millions of dollars for product rights.

The 250 page report reviews the latest developments within the cancer market in terms of emerging therapies, competition, new technology and approaches to treatment, current and future sales, reported deals and looks at possible scenarios for the treatment of different cancer indications during the next five years.

TABLE OF CONTENTS

Contents

Summary and Conclusions

Introduction

Historical Developments and Accomplishments
Objectives of Therapy
Cancer as a Chronic Disease
Scope of Report

Overall View of Agents in Development

Anthracyclines and Antibiotics

Caelyx, Daunoxome, Myocet, Valrubicin
Products in Clinical Trials
Products and Projects in Preclinical Trials
Indications for Products in Clinical Trials
Scenario for New Drug Launches
Sales and Market 2001-2010

Alkylating Agents and DNA Repair Inhibitors

Gliadel, Lobaplatin, Oxaliplatin, Temozolomide
Products in Clinical Trials
Products and Projects in Preclinical Trials
Indications for Products in Clinical Trials
Scenario for New Drug Launches
Sales and Market 2001-2010

Antimetabolites and Inhibitors of DNA and RNA Synthesis

Gemcitabine, Capecitabine, UFT, Pentostatin
Products in Clinical Trials
Products and Projects in Preclinical Trials
Indications for Products in Clinical Trials
Scenario for New Drug Launches
Sales and Market 2001-2010

Topoisomerase Inhibitors

Irinotecan, Topotecan
Products in Clinical Trials
Products and Projects in Preclinical Trials
Indications for Products in Clinical Trials
Scenario for New Drug Launches
Sales and Market 2001-2010

Drugs that Modify Cell Structure and Mitosis

Paclitaxel, Docetaxel
Products in Clinical Trialsv Novel Formulations of Paclitaxel
Epothilones
Products and Projects in Preclinical Trials
Indications for Products in Clinical Trials
Scenario for New Drug Launches
Sales and Market 2001-2010

Hormonal (Endocrine) Drugs

Drugs for Breast Cancer
Anastrazole, Letrozole, Toremifene, Exemestane, Trilostane, Goserelin
Products in Clinical Trials for Breast Cancer
Products and Projects in Preclinical Trials for Breast Cancer
Sales and Market of Products for Breast Cancer 2001-2010
Drugs for Prostate Cancer
Viadur, Trelestar LA
Products in Clinical Trials for Prostate Cancer
Sales and Market for Products for Prostate Cancer

Signal Transduction Modification

Oncogenes, Oncoproteins, Tumor Suppresor Genes
Receptor Linked Enzymes, Receptor/Non receptor Tyrosine Kinases
Receptor Linked Threonine and Serine Kinases
Receptor Linked Tyrosine Phosphatases
Cell Cycle Control and its Modulation for Drug Design
Alitretinoin, Arsenic trioxide, Bexarotene, Arglabin, Imatinib
Products in Clinical and Preclinical Development
Ras Pathway Inhibitors
Retinoids
Inhibitors of Protein Kinase A and C
Inhibitors of: EGF, HER-2/neu, Bcl, C-myc, Fas/Fas Ligand, Mtor, CDKs
Miscellaneous Targets for Drug Development
Indications for Products in Clinical Trials
Scenario for Product Launches

Angiogenesis and Tumor Metastasis

Endogenous Factors Promoting and Inhibiting Angiogenesis
Products in Clinical and Preclinical Trials that Inhibit Angiogenesis
Indications for Products in Clinical Trials
Scenario for New Product Launches 2004-2008

Telomerase Inhibition

Histone Deacetylase Inhibition

Photodynamic Therapy

Porphimer Sodium, Temoporphin, Metvix
Products in Clinical Trials

Drug Resistance

Products in Clinical and Preclinical Trials

Miscellaneous Drugs in Clinical Trials and Indications

Monoclonal Antibodies and Protein Conjugates

Objectives in Cancer Therapy
Problems and Limitations of Therapy
Alemtuzumab, Denileukin Diftitox, Gemtuzumab, Rituximab, Trastuzumab
Products in Clinical and Preclinical Trials
Indications of Products in Clinical and Trials
Scenario for Product Launches 2003-2007
Sales in 2000 and 2001
Estimated Sales 2005-2010

Vaccines

The Immune Response: Roles of T cells and Natural Killer Cells
Tumor Defense Strategies and the Role of Vaccines
Modification of Antigen Presenting Cells
Gene Modification of Tumor Cells
Strategies for Cancer Vaccines: Allogeneic, DNA, Anti-idiotype Vaccines
M-Vax, Melacine, OncoVax-CL
Indications of Products in Clinical and Trialsv Scenario for Product Launches 2003-2007
Estimated Sales 2005-2010

Cytokines

Major Classes of Cytokines
Ancestim, Darbepoietin, Erythropoietin, GM-CSF, G-CSF, Interferons, Interleukins, TNF
Cytokines in Clinical and Preclinical Development
Launch Scenario for New Cytokines
Sales 2001-2010

Oncolytic Viruses and Bacteria

Cancer Drug Discovery Collaborations 2000-2002

Therapeutic

Dr Brian Minter has run Chembio, a consulting practice since 1991. Prior to this he was a research scientist at Pfizer, a marketing manager at DSM Adeno and Solvay Pharmaceuticals and was involved in drug registration at Solvay Pharmaceuticals. He has presented a number of workshops on emerging cancer therapies and is the author of several publications on cancer.